Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
OctoPlus
OctoPlus
Activities:
Manufacturing
Drug Delivery
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m
Aims to build a research base in Leiden, The Netherlands
Manufacturing
OctoPlus signs agreement with pharma company to develop controlled release formulation
Of a therapeutic compound for local delivery into joints
Manufacturing
Octoplus extends drug delivery contract with Top-5 pharma company
Will combine product candidate with Octoplus PolyActive drug delivery technology
Research & Development
OctoPlus extends development agreement with ESBATech
For controlled release product for ophthalmic indications
Drug Delivery
OctoPlus appoints ceo
Jan Hendrik Egberts to replace Simon Sturge
Drug Delivery
OctoPlus signs controlled release technology deal with US firm
Will use PolyActive technology to develop compound
Drug Delivery
OctoPlus wins drug delivery contract expansion
Client will proceed with PolyActive technology evaluation
Subscribe now